These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 35243821)

  • 1. Atypical posterior reversible encephalopathy syndrome associated with Lenvatinib therapy in a patient with metastatic thyroid cancer-A case report.
    Abhishek M; Renuka A; Ujjwal A; Amit C; Vijay P; Vanita N; Nandini M; Kumar P
    Cancer Rep (Hoboken); 2022 Sep; 5(9):e1605. PubMed ID: 35243821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Posterior Reversible Encephalopathy Syndrome after Lenvatinib Therapy in a Patient with Anaplastic Thyroid Carcinoma.
    Osawa Y; Gozawa R; Koyama K; Nakayama T; Sagoh T; Sunaga H
    Intern Med; 2018 Apr; 57(7):1015-1019. PubMed ID: 29225265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Posterior Reversible Encephalopathy Syndrome as an Adverse Effect of Lenvatinib in a Patient with Papillary Thyroid Carcinoma: A Case Report.
    Buenaventura DC; Vargas-Sierra H; Aristizabal-Henao N; Torres-Grajales JL; Aguilar-Londono C; Gutierrez-Restrepo J
    Int J Endocrinol Metab; 2023 Jul; 21(3):e136900. PubMed ID: 38028246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A man in his 50s with neurological symptoms during cancer treatment.
    Aanes SG; Nieder C; Prytz J; Odeh F
    Tidsskr Nor Laegeforen; 2018 Oct; 138(17):. PubMed ID: 30378405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Posterior Reversible Encephalopathy Syndrome after Lenvatinib Therapy in a Patient with Olfactory Neuroblastoma.
    Tseng YJ; Chen CN; Hong RL; Kung WM; Huang AP
    Brain Sci; 2022 Dec; 13(1):. PubMed ID: 36672016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Posterior reversible encephalopathy syndrome possibly induced by pemetrexed maintenance therapy for lung cancer: a case report and literature review.
    Smets GJ; Loyson T; Van Paesschen W; Demaerel P; Nackaerts K
    Acta Clin Belg; 2018 Oct; 73(5):382-388. PubMed ID: 29173113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Posterior reversible encephalopathy syndrome secondary to acute post-streptococcal glomerulonephritis in a child: a case report from the Tibetan plateau.
    Bazhu ; Shi Y; Ren S; Shu L; Li Q
    BMC Neurol; 2022 Jun; 22(1):225. PubMed ID: 35717141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Posterior reversible encephalopathy syndrome.
    Lamy C; Oppenheim C; Mas JL
    Handb Clin Neurol; 2014; 121():1687-701. PubMed ID: 24365441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Posterior reversible encephalopathy syndrome (PRES) with sub-arachnoid haemorrhage after bevacizumab and 5-FU.
    Massey J
    J Clin Neurosci; 2017 Jun; 40():57-59. PubMed ID: 28238523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions.
    Fugate JE; Rabinstein AA
    Lancet Neurol; 2015 Sep; 14(9):914-925. PubMed ID: 26184985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lenvatinib: first global approval.
    Scott LJ
    Drugs; 2015 Apr; 75(5):553-60. PubMed ID: 25795101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generalised reversible encephalopathy syndrome: a variant of posterior reversible encephalopathy syndrome (PRES).
    Kunzmann J; Wolf H; Oberndorfer S
    BMJ Case Rep; 2015 Nov; 2015():. PubMed ID: 26611477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacology and drug-drug interactions of lenvatinib in thyroid cancer.
    Fogli S; Gianfilippo G; Cucchiara F; Del Re M; Valerio L; Elisei R; Danesi R
    Crit Rev Oncol Hematol; 2021 Jul; 163():103366. PubMed ID: 34051303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Posterior reversible encephalopathy syndrome (PRES) induced by pazopanib, a multi-targeting tyrosine kinase inhibitor, in a patient with soft-tissue sarcoma: case report and review of the literature.
    Deguchi S; Mitsuya K; Nakasu Y; Hayashi N; Katagiri H; Murata H; Wasa J; Takahashi M; Endo M
    Invest New Drugs; 2018 Apr; 36(2):346-349. PubMed ID: 29067537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Importance of correctly interpreting magnetic resonance imaging to diagnose posterior reversible encephalopathy syndrome associated with HELLP syndrome: a case report.
    Tetsuka S; Nonaka H
    BMC Med Imaging; 2017 May; 17(1):35. PubMed ID: 28545408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenvatinib: Role in thyroid cancer and other solid tumors.
    Cabanillas ME; Habra MA
    Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detecting the Uncommon Imaging Manifestations of Posterior Reversible Encephalopathy Syndrome (PRES) in Adults: a Comprehensive Illustrated Guide for the Trainee Radiologist.
    Khan IR; Pai V; Mundada P; Sitoh YY; Purohit B
    Curr Probl Diagn Radiol; 2022; 51(1):98-111. PubMed ID: 33257096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atypical posterior reversible encephalopathy syndrome with albuminocytological dissociation and late emerging neuroradiological findings: A case report.
    Unsal Bilgin YO; Eskut N; Koskderelioglu A; Gedizlioglu M
    Postgrad Med; 2021 Jan; 133(1):108-111. PubMed ID: 32880496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The many faces of posterior reversible encephalopathy syndrome.
    Stevens CJ; Heran MK
    Br J Radiol; 2012 Dec; 85(1020):1566-75. PubMed ID: 23175479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gastrointestinal perforation related to lenvatinib, an anti-angiogenic inhibitor that targets multiple receptor tyrosine kinases, in a patient with metastatic thyroid cancer.
    Date E; Okamoto K; Fumita S; Kaneda H
    Invest New Drugs; 2018 Apr; 36(2):350-353. PubMed ID: 29018997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.